Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$58 Mln
P/E Ratio
--
P/B Ratio
2.02
Industry P/E
--
Debt to Equity
0
ROE
-8.07 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-2.48
CFO
$-130.28 Mln
EBITDA
$-174.03 Mln
Net Profit
$-139.19 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cyclacel Pharmaceuticals (CYCC)
| -16.14 | 3.11 | -17.03 | -79.12 | -77.80 | -65.25 | -60.42 |
|
BSE Sensex
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cyclacel Pharmaceuticals (CYCC)
| -85.69 | -73.31 | -82.78 | -50.19 | -41.72 | 10.74 | -65.03 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.73 | 78.84 | -- | -62.96 | |
| 8.54 | 801.08 | -- | -69.5 | |
| 300.25 | 8,705.27 | 22.77 | 66.44 | |
| 25.49 | 2,881.32 | -- | -14.59 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1... inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Read more
President, CEO & Executive Director
Mr. Spiro George Rombotis
President, CEO & Executive Director
Mr. Spiro George Rombotis
Headquarters
Kuala Lumpur
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cyclacel Pharmaceuticals Inc (CYCC) stood at $ 8 Mln as on 31-Mar-25
The share price of Cyclacel Pharmaceuticals Inc (CYCC) is $0.32 (NASDAQ) as of 28-Apr-2025 10:42 EDT. Cyclacel Pharmaceuticals Inc (CYCC) has given a return of -77.8% in the last 3 years.
Cyclacel Pharmaceuticals Inc (CYCC) has a market capitalisation of $ 58 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Cyclacel Pharmaceuticals Inc (CYCC) is 2.02 times as on 25-Apr-2025, a 12% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Cyclacel Pharmaceuticals Inc (CYCC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cyclacel Pharmaceuticals Inc (CYCC) and enter the required number of quantities and click on buy to purchase the shares of Cyclacel Pharmaceuticals Inc (CYCC).
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
The CEO & director of Mr. Spiro George Rombotis. is Cyclacel Pharmaceuticals Inc (CYCC), and CFO & Sr. VP is Mr. Spiro George Rombotis.
There is no promoter pledging in Cyclacel Pharmaceuticals Inc (CYCC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
867
|
|
|
290
|
|
|
80
|
|
|
8
|
| Cyclacel Pharmaceuticals Inc. (CYCC) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-55050
|
|
Net Margin(%)
|
-66878.26
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cyclacel Pharmaceuticals Inc (CYCC) was $0 Mln.
$0.04
(
